logo

For the Inventor, By the Inventor

New York, NY, United States of America

Anavex Life Sciences Corp.


USPTO Granted Patents = 27



Trademarks = 3

Forward Citations = 19

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Christopher U Missling (18 out of 19 patents)

silverMedal Daniel Mark Ledger (3 out of 6 patents)

bronzeMedal Linda Sharon Daintree (3 out of 7 patents)

4.  Lucy Anne Leonard (3 out of 3 patents)

5.  Peter York (3 out of 5 patents)

6.  Alani Selvey (3 out of 3 patents)

7.  Marco Cecchi (2 out of 2 patents)

8.  Alexandre Vamvakides (2 out of 2 patents)

9.  Cameron Durrant (1 out of 2 patents)

10.  Missling U Christopher (1 out of 1 patent)

11.  Durrant Cameron (1 out of 1 patent)

12.  Tangui Maurice (1 out of 1 patent)

13.  Gervais Neliat (1 out of 1 patent)

14.  Mohammad Michel Afshar (1 out of 1 patent)

15.  Frédéric Parmentier (1 out of 1 patent)


27 patents:

1. 12383526 - Optimized sigma-1 agonist method of responder selection and treatment (2025-08-12),
2. 12285403 - A2-73 as a therapeutic for insomnia, anxiety and agitation (2025-04-29),
3. 12280034 - Sigma-1 receptor agonist systolic blood pressure therapy (2025-04-21),
4. 12208079 - Enantiomers of A2-73, analogues, and sigma agonist activity (2025-01-28),
5. 12180174 - A2-73 crystalline polymorph compositions of matter and methods of use thereof (2024-12-31),
6. 12138240 - Treatment of cardiac dysfunction (2024-11-12),
7. 11896590 - Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof (2024-02-13),
8. 11839600 - Neurodevelopmental disorder therapy (2023-12-12),
9. 11813242 - A2-73 as a therapeutic for insomnia, anxiety, and agitation (2023-11-14),
10. 11690821 - A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy (2023-07-04),
11. 11661405 - Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions (2023-05-30),
12. 11622955 - Sigma-1 receptor agonist systolic blood pressure therapy (2023-04-11),
13. 11498908 - A2-73 crystalline polymorph compositions of matter and methods of use thereof (2022-11-15),
14. 11446275 - Neurodevelopmental disorder therapy (2022-09-20),
15. 11337953 - A2-73 as a therapeutic for insomnia, anxiety, and agitation (2022-05-24),
Anavex Life Sciences is a biopharmaceutical company focused on the development of innovative therapies to treat neurodegenerative and neurodevelopmental diseases. Our proprietary precision medicine approach utilizes powerful computational drug discovery platforms to identify potential drug candidates for clinical trials. We are committed to improving the quality of life for patients suffering from Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system disorders.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 13 2026

27 Patents

#278 in New York, NY

#675 in New York

#12,023 in US

#23,327 in the World

...
New York, NY, United States of America

Anavex Life Sciences Corp.

Forward Citations = 19

15 inventors:

goldMedal Christopher U Missling (18 out of 19 patents)

silverMedal Daniel Mark Ledger (3 out of 6 patents)

bronzeMedal Linda Sharon Daintree (3 out of 7 patents)

4.  Lucy Anne Leonard (3 out of 3 patents)

5.  Peter York (3 out of 5 patents)

Please report any incorrect information to support@idiyas.com
Loading…